International Psoriasis Council

Advancing Knowledge. Improving Care.

Meet our Newest Councilors

We are thrilled to announce our newest IPC Councilors for 2023 and extend a warm welcome to José Manuel Carrascosa, Xiang Chen, Álvaro González-Cantero, Emmanuel Mahé, Yuling Shi, Liangdan Sun, Alex Tsoi, and Margarita Velásquez. The IPC Board of Directors confirmed these impressive individuals in March for their unwavering dedication to psoriasis and their unrelenting commitment to improving patient care for psoriasis patients across the globe.

As IPC Councilors, these experts will serve as trusted advisors, lending their invaluable global expertise on psoriasis research, treatment, and education to support all IPC programs, events, and initiatives.

We invite you to learn more about our newest Councilors and their extensive backgrounds by reading their biographies. We are confident that their contributions will help further our mission to advance psoriasis care globally.

José-Manuel Carrascosa Carrillo, MD, PhD

University Hospital Germans Trias í Pujol; Autonomous University of Barcelona

Badalona, Spain

IPC Councilor

Bio

Xiang Chen, MD, PhD

Dept. Dermatology, Xiangya Hospital, Central South

Changsha, China

Bio

Álvaro González-Cantero, MD, PhD

Hospital Ramón y Cajal University Hospital

Madrid, Spain

IPC Councilor

Bio

Emmanuel Mahé , MD, PhD

Hôspital Victor Dupouy

Argenteuil, France

IPC Councilor

Bio

Yuling Shi, MD, PhD

Shanghai Skin Disease Hospital, Tongji University School of Medicine

Shanghai, China

IPC Councilor

Bio

Liangdan Sun, MD, PhD

Health Science Center of North China University of Science and Technology

Hebei Province, China

IPC Councilor

Bio

Alex Tsoi, MS, PhD

University of Michigan

Ann Arbor, Michigan, United States

IPC Councilor

Bio

Margarita María Velásquez Lopera, MD, PhD

University of Antioquia

Medellín, Colombia

IPC Councilor

Bio

Categories

Recent Posts

Next Generation of Leaders: 2025 IPC Fellows Transition to Jr. Councilors

Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic Advances, and Emerging Research

A man in a suit smiles at the camera next to text that reads, World Psoriasis Experts Give Their Take on Current, Hot, or Controversial Topics like Biologics in Psoriasis Management. EXPERT COMMENTARY.

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026